Nebulized formoterol fumarate: Dose selection and pharmacokinetics

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 5, 2008, Pages 818-823

  Gross, Nicholas J ^a   Kerwin, Edward ^b   Levine, Bernard ^c   Kim, Kenneth T ^d   Denis Mize, Kimberly ^e   Hamzavi, Mohammad ^e   Carpenter, Michelle ^f   Rinehart, Mike ^f  

^a HINES VA HOSPITAL   (United States)

^b Clinical Research Institute of Southern Oregon   (United States)

^c Pulmonary Associates   (United States)

^d West Coast Clinical Trials LLC   (United States)

^e Dey Laboratories   (United States)

^f NONE

Author keywords

Airways obstruction; Bronchodilator; COPD; Dose ranging; Formoterol; LABA; Nebulization; Pharmacokinetics

Indexed keywords

FORMOTEROL FUMARATE; PLACEBO; PREDNISONE; STEROID;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BREATHING RATE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG URINE LEVEL; DRY POWDER; ECG ABNORMALITY; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; MALE; MULTICENTER STUDY; NEBULIZER; PHARMACODYNAMICS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOLUTIONS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 51049107684     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.07.002     Document Type: Article

References (20)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555. http://www.goldcopd.com Available from: http://www.goldcopd.com
2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152 (1994) S77-S121
3. Boe J., Dennis J.H., and O'Driscoll B.R. European respiratory society guidelines on the use of nebulizers. Eur Respir J 18 (2001) 228-242
4. O'Donohue W.J. Guidelines for the use of nebulizers in the home and at domiciliary sites. Report of a consensus conference. National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Chest 109 (1996) 814-820
5. American Association for Respiratory Care. AARC supports patient education on MDIs/DPIs, appropriate dispensing fee for nebulizer drugs in new comments. Available from: 〈http://www.aarc.org/headlines/phyfee/index.asp〉; 2007 [accessed 26.03.07].
6. Jarvis S., Ind P.W., and Shiner R.J. Inhaled therapy in elderly COPD patients: time for re-evaluation?. Age Aging 36 (2007) 213-218
7. Mestitz H., Copland J.M., and McDonald C.F. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest 96 (1989) 1237-1240
8. Blake K.V., Hoppe M., Harman E., and Hendeles L. Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Chest 101 (1992) 309-315
9. ®. Respir Med 92 (1998) 1017-1021
10. Kottakis J., Della Cioppa G., Creemers J., Greefhorst L., Leclerc V., Pistelli R., et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 9 (2002) 107-115
11. ® Aerolizer™) with salbutamol (Ventodisk™). Respir Med 95 (2001) 817-821
12. Palmqvist M., Persson G., Lazer L., Rosenberg J., Larsson P., and Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10 (1997) 2484-2489
13. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2005) 948-968
14. Donohue J.F. Minimal clinically important differences in COPD lung function. J COPD 2 (2005) 111-124
15. Derom E., Strandgarden K., Schelfhout V., Borgstrom L., and Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med 101 (2007) 1931-1941
16. Maesen F.P., Costongs R., Smeets S.J., Zweers P.G., and Goedhart D.M. Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 101 (1992) 1376-1381
17. Cazzola M., Matera M.G., Santangelo G., Vinciguerra A., Rossi F., and D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 89 (1995) 357-362
18. Guhan A.R., Cooper S., Obome J., Lewis S., Bennett J., and Tattersfield A.E. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 55 (2000) 650-656
19. Foradil [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corp.
20. Lecaillon J.B., Kaiser G., Palmisano M., Morgan J., and Della Cioppa G. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via aerolizer™. Eur J Clin Pharmacol 55 (1999) 131-138